

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**NOTICE OF THE 2026 SECOND EXTRAORDINARY
SHAREHOLDERS' GENERAL MEETING**

NOTICE IS HEREBY GIVEN that the 2026 second extraordinary shareholders' general meeting (the **"EGM"**) of Shanghai HeartCare Medical Technology Corporation Limited (the **"Company"**, together with its subsidiaries, the **"Group"**) will be held at Sealmedical Hall, 4/F, Building 8, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC on Thursday, September 3, 2026 at 10:00 a.m. for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise defined, capitalized terms used in this notice shall have the same meanings as those defined in the circular of the Company dated August 14, 2026 (the **"Circular"**).

SPECIAL RESOLUTIONS

1. To consider and approve the proposed Issue of A Shares as follows (each and every items as a separate resolution):
 - i. Class of new Shares to be issued: Ordinary Shares (A Shares).
 - ii. Place of listing: All A Shares will be listed and traded on the Sci-Tech Board of the Shanghai Stock Exchange.
 - iii. Nominal value of new Shares to be issued: RMB1.00 each.
 - iv. Issue size: The Company proposes to issue not more than 7,025,592 new A Shares (excluding the number of A Shares to be issued pursuant to the over-allotment option), representing approximately 18.1% of the share capital of the Company (excluding treasury Shares) as of the Latest Practicable Date, and approximately 15.3% of the enlarged share capital upon completion of the Issue of A Shares

(excluding the number of A Shares to be issued pursuant to the over-allotment option). The Issue of A Shares only involves issue of new Shares, and will not involve sale of Shares by existing Shareholders. The Issue of A Shares can adopt the over-allotment option, which shall not exceed 15% of the Shares initially available under the Issue of A Shares. The final issue size will be determined by the Board after consultation with the lead underwriter(s) according to the authorization (if granted at the EGM), and be subject to final number of A Shares registered by the CSRC.

- v. Target subscribers: Qualified price consultation participants, PRC natural persons, legal persons and other investors who fulfill the relevant rules and requirements relating to the Sci-Tech Board published by the Shanghai Stock Exchange and the CSRC (excluding those in respect of which subscription has been prohibited by laws, regulations and regulatory documents of the PRC).
- vi. Method of issuance: The Issue of A Shares will be conducted through a combination of off-line placement to the price consultation participants and offering by way of on-line subscription by public investors, or other methods of issuance approved by the securities regulatory authorities (including but not limited to offering to strategic investors).
- vii. Method of underwriting: The Issue of A Shares will be underwritten by the lead underwriter(s) by way of standby commitment.
- viii. Pricing methodology and issue price: The issue price for the A Shares will be determined by the Company and the lead underwriter(s) in accordance with applicable laws and regulations, or by other pricing methods recognized by the CSRC and the Shanghai Stock Exchange.
- ix. Schedule of issuance: The Company will proceed with the Issue within 12 months after the Shanghai Stock Exchange issues the approval opinion and CSRC approves the Issue. The Board and the lead underwriter(s) will determine the listing date for the A Shares after the CSRC agrees to the registration of the A Shares and after completion of the offering.

- x. Use of the proceeds: The tentative proceeds raised by the Company from the Proposed Issue of A Shares (assuming a preliminary net proceeds of RMB508.0 million representing an implied preliminary offer price of RMB72.31 per A Share, which may be subject to revision, including the number of offer shares to be determined at a subsequent stage) will be used for the projects outlined below (the “**Projects**”) after deducting the issuance expenses. The actual proceeds to be raised from the Proposed Issue of A Shares will be subject to actual market conditions, the Company’s operating results and actual funding needs for various expenditure and investment plans.

No.	Project name	Proposed amount from proceeds raised (RMB) (million)
1	Manufacturing of neuro-interventional devices	155.0
2	Vascular intervention devices research, development and manufacturing	132.0
3	Research, development and registration	171.0
4	Supplement working capital	50.0
Total		508.0

Before the proceeds raised from the Issue of A Shares are in place, the Company may make an initial investment with its own funds according to the needs of the Projects. As at the Latest Practicable Date, the Projects are in the preliminary preparation stage, and only preliminary investment has been made by now. The Company will not use the global offering’s proceeds from H Shares offering for the construction or implementation of these Projects. After the proceeds raised are in place, the Company can replace the initial investment funds with the proceeds raised from the Issue of A Shares.

- xi. Validity period of the resolutions: The resolutions will be valid for a period of 12 months from the date of approval at the EGM.

2. To consider and approve the authorization to the Board of Directors to fully handle matters in connection with the Issue of A Shares and the listing on the Sci-Tech Board.

The authorization proposed to be granted to the Board shall include without limitation:

- i. The formulation and implementation of the specific proposals for this issuance, including but not limited to specific matters such as issue size, target subscribers, method of issuance, timing of issuance, pricing methodology, issue price, method of subscription and strategic placement (including the placement ratio, placement targets, etc.) and other matters related to the issue and listing in accordance with laws and regulations, the relevant requirements of securities regulatory authorities and the securities market conditions, and within the framework and in accordance with the principles adopted by the Shareholders at the EGM.
- ii. The performance of all procedures relating to the Proposed Issue of A Shares and listing on the Sci-Tech Board, including the procedures relating to registration, approval, registration, review, filing with the relevant regulatory authorities, and to sign, execute, amend and complete all necessary documents to be submitted to the government, authority and organization.
- iii. The appropriate adjustment to the specific matters relating to the Proposed Issue of A Shares and listing on the Sci-Tech Board within the effective period for the Issue of A Shares, including the amendment and submission of listing application materials as required by a change of policies or market circumstances.
- iv. The preparation, amendment, signing, submission, publication, disclosure, implementation, suspension and termination of all agreements, contracts, notice or other documents relating to this issuance and listing (including but not limited to prospectus intentions, prospectus document, sponsoring agreement, underwriting agreement, strategic placement agreement, listing agreement, engagement agreements of intermediaries for the Issue of A Shares and listing on the Sci-Tech Board), the engagement of sponsor(s), underwriter(s), legal adviser(s), auditing firm(s), asset valuer(s), receiving bank(s) and other intermediaries involved in this issuance and listing, and the determination and payment of all expenses relating to this issuance and listing.
- v. The necessary supplement and amendment to the Articles (draft) and the internal management policies of the Company, the “Analysis on Dilution on Immediate Return by the Initial Public Offering of A Shares and Recovery Measures for the

Immediate Return, the “Three-Year Dividend Distribution Plan for Shareholders after the Initial Public Offering of A Shares and the Listing on the Sci-Tech Board”, the “Share Price Stabilization Plan for the Three Years after the Initial Public Offering of A Shares and the Listing on the Sci-Tech Board” and other application documents and undertakings by the Company according to the applicable laws and regulations, requirements and suggestions of the relevant securities regulatory authorities or according to the actual conditions of this issuance.

- vi. The appropriate adjustments to be made to the relevant matters of the investment projects funded by the proceeds raised according to the implementation process of this issuance and listing, market conditions, policy adjustments and comments of the relevant securities regulatory authorities, including but not limited to the confirmation of the process of the investment projects, the allocation of funds when applying the proceeds raised, the confirmation of a special deposit account for the proceeds raised, etc., so long as such adjustments comply with applicable laws.
- vii. After the completion of the Issue of A Shares and listing on the Sci-Tech Board, to handle the procedures for amending the Articles of Association, capital verification, commercial registration changes and relevant approvals, registrations and filings based on the results of this issuance.
- viii. According to the implementation process of this issuance, in accordance with the undertakings of each Shareholder, handling the matters of listing of the A Shares on the Shanghai Stock Exchange and settlement of shareholdings at the China Securities Depository and Clearing Co., Ltd. (including but not limited to the registration, circulation and lock-up of shares).
- ix. The authorization to handle matters in relation to the opening of the depository account for the funds raised.
- x. To the extent permitted by relevant laws, regulations and regulatory documents, the handling of other matters considered to be necessary, desirable or appropriate for this issuance and listing.

The above authorization, if approved, shall be valid for a period of 12 months from the date of approval at the EGM.

3. To consider and approve the use of proceeds raised from the Issue of A Shares and the listing on the Sci-Tech Board. The proceeds raised by the Company from the proposed Issue of A Shares will be used for the following projects after deducting the issuance expenses:

No.	Project name	Proposed amount from proceeds raised (RMB) (million)
1	Manufacturing of neuro-interventional devices	155.0
2	Vascular intervention devices research, development and manufacturing	132.0
3	Research, development and registration	171.0
4	Supplement working capital	50.0
	Total	<u><u>508.0</u></u>

Before the proceeds raised from the Issue of A Shares are in place, the Company may make an initial investment with its own funds according to the needs of the projects, and after the proceeds raised are in place, the Company can replace the initial investment funds with the proceeds raised from the Issue of A Shares.

After the proceeds raised from the Issue of A Shares are in place, if the proceeds raised from this issuance cannot meet the capital requirements of the above proposed projects, the Company will invest according to the priority of the projects, the shortfall shall be covered by the Company with its own raised funds. If the proceeds raised from this issuance exceeds the capital requirements of the above projects, the surplus amount will be mainly used to supplement working capital and in accordance with the relevant regulations of the regulatory authorities.

4. To consider and approve the proposal for accumulated profit distribution prior to the Issue of A Shares and the listing on the Sci-Tech Board:

As of December 31, 2025, the Company has undistributed accumulated profit of RMB46.8 million. If the Company has undistributed accumulated profit or unrecovered losses before the Issue of A Shares and listing on the Sci-Tech Board, then it is proposed that the new and existing Shareholders shall share such profit or bear such losses in proportion to their respective shareholdings after the Issue of A Shares and listing on the Sci-Tech Board.

5. To consider and approve the analysis on dilution on immediate return by the Company's initial public offering of A Shares and adoption of recovery measures for the immediate return.
6. To consider and approve the Company's three-year dividend distribution plan for Shareholders and profit distribution policy after the Company's initial public offering of A Shares and the listing on the Sci-Tech Board.
7. To consider and approve the Company's Share Price Stabilization Plan for the Three Years after the Initial Public Offering of A Shares and the Listing on the Sci-Tech Board.
8. To consider and approve the undertakings and restraining measures relating to the Issue of A Shares and listing on the Sci-Tech Board, and to authorize the Board to make appropriate undertakings for the purpose of the Issue of A Shares in accordance with the laws, regulations and regulatory documents of the PRC, the relevant regulations and policies of the securities regulatory departments, and combining the review for listing on the Sci-Tech Board in practice and the actual situation of the Company
9. To consider and approve the status of major transactions with related parties during the Track Record Period (i.e. the three years ended December 31, 2023, 2024 and 2025 and the six months ended June 30, 2026).
10. To consider and approve the proposed amendments to the articles of association of the Company.

ORDINARY RESOLUTIONS

11. To consider and approve the amendment to the “Rules of Procedures for the Shareholders’ General Meetings”.
12. To consider and approve the amendment to the “Rules of Procedures for the Board of Directors”.
13. To consider and approve the amendments to or adoption of each of the following internal management policies (each and every items as an ordinary resolution):
 - (a) the “Decision-Making Policies for Related (Connected) Transactions”;
 - (b) the “Terms of Reference for the Independent Non-executive Directors”;
 - (c) the “Management Policies for External Guarantees ”;
 - (d) the “Management Measures for External Investments”;
 - (e) the “Management Policies for Raised Proceeds”; and
 - (f) the “Implementation Rules for Online Voting”.
14. To consider and approve the proposed amendments to the 2025 H Share Incentive Scheme.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, August 14, 2026

Notes:

1. Any voting at the EGM shall be taken by poll. Any shareholder of the Company entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and, on a poll, vote instead of him/her. A proxy need not be a member of the Company.

2. The instrument appointing a proxy shall be in writing under the hand of the appointer or of his/her attorney duly authorized in writing or, if the appointer is a corporation, either under its seal or under the hand of any officer or attorney duly authorized.
3. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a notarially certified copy of such power or authority, must be deposited with Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares) or the Company's registered office at Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC (for holders of Unlisted Shares) as soon as practicable but in any event not less than 24 hours before the time appointed for holding the EGM (i.e., at or before 10:00 a.m. on Wednesday, September 2, 2026 (Hong Kong Time)), or any adjourned meeting thereof (as the case may be).
4. Completion and return of the form of proxy shall not preclude the shareholders of the Company from attending and voting in person at the EGM or at any adjourned meeting thereof (as the case may be) should they so wish, and in such event, the form of proxy shall be deemed to be revoked.
5. Where there are joint registered holders of any share, any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he/she was solely entitled thereto, but if more than one of such joint holders are present at the EGM, whether in person or by proxy, the joint registered holder present whose name stands first on the register of members of the Company in respect of the shares shall alone be entitled to vote in respect thereof.
6. For the purpose of determining the Shareholders of the Company entitled to attend and vote at the EGM, the register of members of the Company will be closed from Monday, August 31, 2026 to Thursday, September 3, 2026 (both days inclusive). The record date for determining the entitlement of the Shareholders of the Company to attend and vote at the EGM will be September 3, 2026. In order to qualify for the entitlement to attend and vote at the above EGM, H Shareholders must lodge all transfer forms accompanied by the relevant H Share certificates with the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong by no later than 4:30 p.m. on Friday, August 28, 2026.
7. The EGM is expected to take less than half a day. Shareholders who attend the EGM shall be responsible for their own travel and accommodation expenses. Shareholders may contact the Investor Relations Department of the Company at +86 21 5897 5056 or ir@heartcare.com.cn for any enquiries in respect of the EGM.
8. Shareholders of the Company whose names appear on the register of members of the Company on Thursday, September 3, 2026 will be entitled to attend and vote at the EGM or any adjourned meetings.
9. All times set out in this notice refer to Hong Kong local time.

As at the date of this notice, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.